Funds raised through this financing will allow BioVascular to complete ongoing clinical trials of its two compounds, saratin and BVI-007. The company has raised a total of $18.87 million to date. In connection with the financing, Martin partner of BB Biotech will join BioVascular’s board of directors.
John Parrish, CEO of BioVascular, said: “With the support of Domain Associates and Merck KGaA, BioVascular has built a solid strategy for advancing our two clinical candidates.”